EDSA — Edesa Biotech Income Statement
0.000.00%
Last trade - 00:00
- $14.90m
- $10.63m
- 30
- 14
- 56
- 25
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 9 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.411 | 0.329 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.31 | 0.311 | 0 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 3.24 | 6.73 | 23.7 | 18.4 | 9.22 |
Operating Profit | -2.83 | -6.4 | -23.7 | -18.4 | -9.22 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.78 | -6.36 | -13.3 | -17.5 | -8.37 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.78 | -6.36 | -13.3 | -17.5 | -8.37 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.78 | -6.36 | -13.3 | -17.5 | -8.37 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.78 | -6.36 | -13.3 | -17.5 | -8.37 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.86 | -5.18 | -7.73 | -7.37 | -2.93 |
Dividends per Share |